The company develops miniature human intestine models to diagnose and study gut diseases. By integrating organ‑on‑a‑chip technology, their micro‑intestines replicate key physiological functions, enabling researchers and clinicians to assess disease mechanisms and test therapeutics more accurately than traditional cell cultures.
Funding
Funding not disclosed
Founders
Product
Problem
Current models for studying gastrointestinal diseases rely on static cell cultures or animal experiments that fail to capture the complex physiology of the human intestine, limiting the ability to understand disease mechanisms and predict therapeutic responses.
Solution
Neigesbiotech creates miniature human intestine models using organ‑on‑a‑chip technology that faithfully reproduce key intestinal functions such as barrier formation, nutrient absorption, and micro‑environmental cues. These micro‑intestines provide a physiologically relevant platform for researchers and clinicians to investigate gut disease pathways, evaluate drug efficacy, and explore personalized treatment options. By offering a scalable, human-relevant alternative to traditional models, the platform accelerates discovery and reduces reliance on animal testing.
Target Audience
Primary users are pharmaceutical researchers, academic labs, and clinical teams focused on gastrointestinal disease modeling and drug development.
Features
- Microfluidic chip that supports 3D culture of human intestinal epithelial cells with dynamic flow conditions
- Integrated barrier integrity monitoring via transepithelial electrical resistance (TEER) sensors
- Capability to co‑culture with microbiota or immune cells to mimic the intestinal microenvironment
- Real‑time imaging ports for high‑resolution microscopy and functional assays
- Standardized, reproducible format compatible with existing laboratory automation and screening workflows